1
|
Ribeiro G, Ferreira G, Menda UD, Alexandre M, Brites MJ, Barreiros MA, Jana S, Águas H, Martins R, Fernandes PA, Salomé P, Mendes MJ. Sub-Bandgap Sensitization of Perovskite Semiconductors via Colloidal Quantum Dots Incorporation. Nanomaterials (Basel) 2023; 13:2447. [PMID: 37686955 PMCID: PMC10489900 DOI: 10.3390/nano13172447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 08/20/2023] [Accepted: 08/27/2023] [Indexed: 09/10/2023]
Abstract
By taking advantage of the outstanding intrinsic optoelectronic properties of perovskite-based photovoltaic materials, together with the strong near-infrared (NIR) absorption and electronic confinement in PbS quantum dots (QDs), sub-bandgap photocurrent generation is possible, opening the way for solar cell efficiencies surpassing the classical limits. The present study shows an effective methodology for the inclusion of high densities of colloidal PbS QDs in a MAPbI3 (methylammonium lead iodide) perovskite matrix as a means to enhance the spectral window of photon absorption of the perovskite host film and allow photocurrent production below its bandgap. The QDs were introduced in the perovskite matrix in different sizes and concentrations to study the formation of quantum-confined levels within the host bandgap and the potential formation of a delocalized intermediate mini-band (IB). Pronounced sub-bandgap (in NIR) absorption was optically confirmed with the introduction of QDs in the perovskite. The consequent photocurrent generation was demonstrated via photoconductivity measurements, which indicated IB establishment in the films. Despite verifying the reduced crystallinity of the MAPbI3 matrix with a higher concentration and size of the embedded QDs, the nanostructured films showed pronounced enhancement (above 10-fold) in NIR absorption and consequent photocurrent generation at photon energies below the perovskite bandgap.
Collapse
Affiliation(s)
- G. Ribeiro
- i3N/CENIMAT, Department of Materials Science, NOVA School of Science and Technology and CEMOP/UNINOVA, Campus de Caparica, 2829-516 Caparica, Portugal (M.A.); (S.J.); (H.Á.)
- INL, International Iberian Nanotechnology Laboratory, 4715-330 Braga, Portugal; (P.A.F.); (P.S.)
| | - G. Ferreira
- i3N/CENIMAT, Department of Materials Science, NOVA School of Science and Technology and CEMOP/UNINOVA, Campus de Caparica, 2829-516 Caparica, Portugal (M.A.); (S.J.); (H.Á.)
| | - U. D. Menda
- i3N/CENIMAT, Department of Materials Science, NOVA School of Science and Technology and CEMOP/UNINOVA, Campus de Caparica, 2829-516 Caparica, Portugal (M.A.); (S.J.); (H.Á.)
| | - M. Alexandre
- i3N/CENIMAT, Department of Materials Science, NOVA School of Science and Technology and CEMOP/UNINOVA, Campus de Caparica, 2829-516 Caparica, Portugal (M.A.); (S.J.); (H.Á.)
| | - M. J. Brites
- LNEG, Estrada do Paço do Lumiar, 22, 1649-038 Lisboa, Portugal; (M.J.B.)
| | - M. A. Barreiros
- LNEG, Estrada do Paço do Lumiar, 22, 1649-038 Lisboa, Portugal; (M.J.B.)
| | - S. Jana
- i3N/CENIMAT, Department of Materials Science, NOVA School of Science and Technology and CEMOP/UNINOVA, Campus de Caparica, 2829-516 Caparica, Portugal (M.A.); (S.J.); (H.Á.)
| | - H. Águas
- i3N/CENIMAT, Department of Materials Science, NOVA School of Science and Technology and CEMOP/UNINOVA, Campus de Caparica, 2829-516 Caparica, Portugal (M.A.); (S.J.); (H.Á.)
| | - R. Martins
- i3N/CENIMAT, Department of Materials Science, NOVA School of Science and Technology and CEMOP/UNINOVA, Campus de Caparica, 2829-516 Caparica, Portugal (M.A.); (S.J.); (H.Á.)
| | - P. A. Fernandes
- INL, International Iberian Nanotechnology Laboratory, 4715-330 Braga, Portugal; (P.A.F.); (P.S.)
- CIETI, Departamento de Física, Instituto Superior de Engenharia do Porto, Instituto Politécnico do Porto, 4249-015 Porto, Portugal
- Departamento de Física, Universidade de Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal
| | - P. Salomé
- INL, International Iberian Nanotechnology Laboratory, 4715-330 Braga, Portugal; (P.A.F.); (P.S.)
- i3N, Universidade de Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal
| | - M. J. Mendes
- i3N/CENIMAT, Department of Materials Science, NOVA School of Science and Technology and CEMOP/UNINOVA, Campus de Caparica, 2829-516 Caparica, Portugal (M.A.); (S.J.); (H.Á.)
| |
Collapse
|
2
|
Rousset L, Bohelay G, Gille T, Le Roux-Villet C, Kambouchner M, Levy A, Brauner M, Tandjaoui H, Aucouturier F, Mignot S, Caux F, Prost-Squarcioni C, Alexandre M. Bronchial involvement in mucous membrane pemphigoid: 2 cases and a literature review. Ann Dermatol Venereol 2023; 150:64-70. [PMID: 36435654 DOI: 10.1016/j.annder.2022.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 05/05/2022] [Accepted: 08/30/2022] [Indexed: 11/25/2022]
Affiliation(s)
- L Rousset
- Department of Dermatology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France; Referral Centre for Autoimmune Blistering Diseases (MALIBUL), France
| | - G Bohelay
- Department of Dermatology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France; Referral Centre for Autoimmune Blistering Diseases (MALIBUL), France
| | - T Gille
- Department of Physiology and Functional Explorations, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France; Inserm U1272 "Hypoxia and the Lung", UFR SMBH Léonard de Vinci, Paris 13 University, France
| | - C Le Roux-Villet
- Department of Dermatology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France; Referral Centre for Autoimmune Blistering Diseases (MALIBUL), France
| | - M Kambouchner
- Department of Pathology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
| | - A Levy
- Department of Pathology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
| | - M Brauner
- Department of Radiology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
| | - H Tandjaoui
- Department of Pulmonology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
| | - F Aucouturier
- Department of Immunology, Saint-Louis Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 7 University, 75010 Paris, France
| | - S Mignot
- Department of Immunology, Bichat Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 7 University, 75018 Paris, France
| | - F Caux
- Department of Dermatology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France; Referral Centre for Autoimmune Blistering Diseases (MALIBUL), France
| | - C Prost-Squarcioni
- Department of Dermatology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France; Referral Centre for Autoimmune Blistering Diseases (MALIBUL), France; Histology Laboratory, UFR SMBH Léonard de Vinci, Paris 13 University, Bobigny, France
| | - M Alexandre
- Department of Dermatology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France; Referral Centre for Autoimmune Blistering Diseases (MALIBUL), France.
| |
Collapse
|
3
|
Nocera L, Bravi C, Paciotti M, Piro A, Balestrazzi E, Peraire Lores M, Piramide F, Mottaran A, Sarchi L, Farinha R, D’Hondt F, De Naeyer G, De Groote R, Alexandre M. Robot-assisted radical prostatectomy for prostate cancer: 18-year oncological outcomes from a Belgian high-volume center. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01144-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
4
|
Chaudot F, Sève P, Rousseau A, Alexandre M, Fournie P, Lozac’h P, Keraen J, Servant M, Muller R, Gramont B, Touhami S, Mahmoud H, Quintart P, Dalle S, Lambotte O, Kodjikian L, Jamilloux Y. Inflammation oculaire induite par les inhibiteurs du checkpoint immunitaire. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
5
|
Castel M, Alexandre M, Jelti L, Pham-Ledard A, Viguier M, Bédane C, Tancrède-Bohin E, Musette P, Carvalho P, Cordel N, Caux F, Joly P. Updated French guidelines for the therapeutic management of bullous pemphigoid. Ann Dermatol Venereol 2022; 149:81-91. [PMID: 34702559 DOI: 10.1016/j.annder.2021.08.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 04/19/2021] [Accepted: 08/02/2021] [Indexed: 10/20/2022]
Affiliation(s)
- M Castel
- Department of Dermatology, Rouen University Hospital, University of Normandy, 76000 Rouen, France; Institut National de la Santé et de la Recherche Médicale U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, University of Normandy, 76000 Rouen, France.
| | - M Alexandre
- Department of Dermatology, University of Paris XIII, 93000 Bobigny, France
| | - L Jelti
- Department of Dermatology, Rouen University Hospital, University of Normandy, 76000 Rouen, France
| | - A Pham-Ledard
- Department of Dermatology, University of Bordeaux, 33000 Bordeaux, France
| | - M Viguier
- Department of Dermatology, University of Reims, 51100 Reims, France
| | - C Bédane
- Department of Dermatology, University of Limoges, 87000 Limoges, France
| | - E Tancrède-Bohin
- Department of Dermatology, University of Paris X, 75010 Paris, France
| | - P Musette
- Department of Dermatology, University of Paris XIII, 93000 Bobigny, France
| | - P Carvalho
- Department of Dermatology, Rouen University Hospital, University of Normandy, 76000 Rouen, France
| | - N Cordel
- Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital, Point-à-Pitre, Guadeloupe; Institut National de la Santé et de la Recherche Médicale U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, University of Normandy, 76000 Rouen, France
| | - F Caux
- Department of Dermatology, University of Paris XIII, 93000 Bobigny, France
| | - P Joly
- Department of Dermatology, Rouen University Hospital, University of Normandy, 76000 Rouen, France; Institut National de la Santé et de la Recherche Médicale U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, University of Normandy, 76000 Rouen, France
| |
Collapse
|
6
|
Khitri M, Georgin-Lavialle S, Terrier B, Saadoun D, Piette J, Seguier J, Le Bernerais M, De Moreuil C, Fain O, Denis G, Gerfaud-Valentin M, Grobost V, Alexandre M, Laurence B, Galland J, Dumont A, Devaux M, Hirsch P, Jachiet V, Mekinian A. Comparaison entre Polychondrite atrophiante idiopathique et polychondrite atrophiante associée au VEXAS syndrome : analyse d’une série française de 89 patients. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
7
|
Alexandre M, Águas H, Fortunato E, Martins R, Mendes MJ. Light management with quantum nanostructured dots-in-host semiconductors. Light Sci Appl 2021; 10:231. [PMID: 34785654 PMCID: PMC8595380 DOI: 10.1038/s41377-021-00671-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 10/15/2021] [Accepted: 10/25/2021] [Indexed: 06/13/2023]
Abstract
Insightful knowledge on quantum nanostructured materials is paramount to engineer and exploit their vast gamut of applications. Here, a formalism based on the single-band effective mass equation was developed to determine the light absorption of colloidal quantum dots (CQDs) embedded in a wider bandgap semiconductor host, employing only three parameters (dots/host potential barrier, effective mass, and QD size). It was ascertained how to tune such parameters to design the energy level structure and consequent optical response. Our findings show that the CQD size has the biggest effect on the number and energy of the confined levels, while the potential barrier causes a linear shift of their values. While smaller QDs allow wider energetic separation between levels (as desired for most quantum-based technologies), the larger dots with higher number of levels are those that exhibit the strongest absorption. Nevertheless, it was unprecedently shown that such quantum-enabled absorption coefficients can reach the levels (104-105 cm-1) of bulk semiconductors.
Collapse
Affiliation(s)
- M Alexandre
- i3N/CENIMAT, Department of Materials Science, Faculty of Science and Technology, Universidade NOVA de Lisboa and CEMOP/UNINOVA, Campus de Caparica, 2829-516, Caparica, Portugal.
| | - H Águas
- i3N/CENIMAT, Department of Materials Science, Faculty of Science and Technology, Universidade NOVA de Lisboa and CEMOP/UNINOVA, Campus de Caparica, 2829-516, Caparica, Portugal
| | - E Fortunato
- i3N/CENIMAT, Department of Materials Science, Faculty of Science and Technology, Universidade NOVA de Lisboa and CEMOP/UNINOVA, Campus de Caparica, 2829-516, Caparica, Portugal
| | - R Martins
- i3N/CENIMAT, Department of Materials Science, Faculty of Science and Technology, Universidade NOVA de Lisboa and CEMOP/UNINOVA, Campus de Caparica, 2829-516, Caparica, Portugal
| | - M J Mendes
- i3N/CENIMAT, Department of Materials Science, Faculty of Science and Technology, Universidade NOVA de Lisboa and CEMOP/UNINOVA, Campus de Caparica, 2829-516, Caparica, Portugal.
| |
Collapse
|
8
|
Huard E, Gillibert A, Ferries L, Alexandre M, Duvert-Lehembre S, Corbaux C, Prost-Squarcioni C, Caux F, Delaporte E, Litrowski N, Boulard C, Joly P, Hebert V. Comparaison de l’évolution de la qualité de vie sous traitement des patients atteints de pemphigoïde bulleuse, pemphigoïde cicatricielle ou pemphigus. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Combemale L, Alexandre M, Sitbon I, Pascal F, Soued I, Doan S, Caux F, Prost-Squarcioni C, Le Roux-Villet C. Lichen plan pemphigoïde avec atteinte muqueuse : étude de 12 cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Font G, Staumont-Salle D, Oro S, Seta V, Dupin N, Richard M, Jeudy G, Mallet S, Alexandre M, Le Roux-Villet C, Joly P, Prost-Squarcioni C, Duvert-Lehembre S. Efficacité du rituximab dans les maladies à IgA linéaire : une cohorte rétrospective. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Corbaux P, Lardy-Cleaud A, Alexandre M, Fontanilles M, Levy C, Viansone A, Mailliez A, Debled M, Gonçalves A, Le Du F, Lerebours F, Ferrero JM, Eymard JC, Mouret-Reynier MA, Petit T, Frenel JS, Pons-Tostivint E, Courtinard C, Chaix M, Bachelot T. 280MO Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
12
|
Ferries L, Gillibert A, Duvert‐Lehembre S, Corbaux C, Alexandre M, Prost‐Squarcioni C, Caux F, Delaporte E, Litrowski N, Boulard C, Murrell D, Joly P, Hébert V. Sensitivity to change and correlation between the autoimmune bullous disease quality‐of‐life questionnaires
ABQOL
and
TABQOL
, and objective severity scores. Br J Dermatol 2020; 183:944-945. [DOI: 10.1111/bjd.19173] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- L. Ferries
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de Référence des Maladies Bulleuses Autoimmunes Normandie University Rouen France
| | - A. Gillibert
- Department of Biostatistics Rouen University Hospital and INSERM U1219 Normandie University Rouen France
| | - S. Duvert‐Lehembre
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de Référence des Maladies Bulleuses Autoimmunes Normandie University Rouen France
| | - C. Corbaux
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de Référence des Maladies Bulleuses Autoimmunes Normandie University Rouen France
| | - M. Alexandre
- Department of Dermatology University of Paris XIII Bobigny France
| | | | - F. Caux
- Department of Dermatology University of Paris XIII Bobigny France
| | - E. Delaporte
- Department of Dermatology Claude Huriez University Hospital University of Lille Lille France
| | - N. Litrowski
- Department of Dermatology Jacques Monod Le Havre University Hospital Montivilliers France
| | - C. Boulard
- Department of Dermatology Jacques Monod Le Havre University Hospital Montivilliers France
| | - D.F. Murrell
- Department of Dermatology St George Hospital University of New South Wales Sydney NSW Australia
| | - P. Joly
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de Référence des Maladies Bulleuses Autoimmunes Normandie University Rouen France
| | - V. Hébert
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de Référence des Maladies Bulleuses Autoimmunes Normandie University Rouen France
| |
Collapse
|
13
|
Chen D, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, Maho‐Vaillant M, Prost‐Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski M, Labeille B, Picard‐Dahan C, Paul C, Richard M, Bouaziz J, Duvert‐Lehembre S, Bernard P, Caux F, Alexandre M, Ingen‐Housz‐Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel‐Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot‐Barry M, Dereure O, Sassolas B, Benichou J, Musette P, Joly P. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol 2020; 182:1111-1119. [PMID: 31487383 PMCID: PMC7317434 DOI: 10.1111/bjd.18482] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/29/2019] [Indexed: 12/11/2022]
Abstract
BACKGROUND Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. OBJECTIVES To utilize data collected in a French investigator-initiated, phase III, open-label, randomized controlled trial to demonstrate the efficacy and safety of rituximab and seek approval for its use in PV. METHODS This was an independently conducted post hoc analysis of the moderate-to-severe PV subset enrolled in the Ritux 3 study. Patients were randomized to rituximab plus 0·5 or 1·0 mg kg-1 per day prednisone tapered over 3 or 6 months, or 1·0 or 1·5 mg kg-1 per day prednisone alone tapered over 12 or 18 months, respectively (according to disease severity). The primary end point was complete remission at month 24 without CS (CRoff) for ≥ 2 months, and 24-month efficacy and safety results were also reported. RESULTS At month 24, 34 of 38 patients (90%) on rituximab plus prednisone achieved CRoff ≥ 2 months vs. 10 of 36 patients (28%) on prednisone alone. Median total cumulative prednisone dose was 5800 mg in the rituximab plus prednisone arm vs. 20 520 mg for prednisone alone. Eight of 36 patients (22%) who received prednisone alone withdrew from treatment owing to AEs; one rituximab-plus-prednisone patient withdrew due to pregnancy. Overall, 24 of 36 patients (67%) on prednisone alone experienced a grade 3/4 CS-related AE vs. 13 of 38 patients (34%) on rituximab plus prednisone. CONCLUSIONS In patients with moderate-to-severe PV, rituximab plus short-term prednisone was more effective than prednisone alone. Patients treated with rituximab had less CS exposure and were less likely to experience severe or life-threatening CS-related AEs. What's already known about this topic? Pemphigus vulgaris (PV) is the most common type of pemphigus. Corticosteroids, a standard first-line treatment for PV, have significant side-effects. Although their effects are unproven, adjuvant corticosteroid-sparing agents are routinely used to minimize steroid exposure and corticosteroid-related side-effects. There is evidence that the anti-CD20 antibody rituximab is effective in the treatment of patients with severe recalcitrant pemphigus and in patients with newly diagnosed pemphigus. What does this study add? This study provides a more detailed analysis of patients with PV enrolled in an investigator-initiated trial. Rituximab plus prednisone had a steroid-sparing effect and more patients achieved complete remission off prednisone. Fewer patients experienced grade 3 or grade 4 steroid-related adverse events than those on prednisone alone. This collaboration between academia and industry, utilizing independent post hoc analyses, led to regulatory authority approvals of rituximab in moderate-to-severe PV.
Collapse
|
14
|
Mignard C, Maho-Vaillant M, Prost-Squarcioni C, Calbo S, Golinski ML, Labeille B, Picard-Dahan C, Konstantinou M, Richard MA, Bouaziz J, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Martin L, D’Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Hébert V, Joly P. Facteurs pronostiques de rechute à long terme chez les patients atteints de pemphigus traités par rituximab en première ligne. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
Pinard C, Duvert-Lehembre S, Prost-Squarcioni C, Alsubaiei F, Houivet E, Le Henaff Y, Heas S, Picard-Dahan C, Bernard P, Doutre M, Beylot-Barry M, Richard MA, Delaporte E, Fleuret C, Oro S, D’Incan M, Alexandre M, Caux F, Maillard H, Bénéton N, Hebert V, Joly P. Évaluation d’un questionnaire de sévérité au cours du pemphigus. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
16
|
Haddad N, Bourrat E, Caux F, Grootenboer-Mignot S, Alexandre M, Prost C. Pemphigoïde des muqueuses à laminine 332 dans une fratrie atteinte d’épidermolyse bulleuse jonctionnelle non Herlitz, avec mutations à l’état hétérozygote composite du gène codant la chaine β3 de la laminine 332. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Joly E, Seta V, Plantier F, Alexandre M, Dupin N, Chanal J. Pemphigoïde du pénis. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Jelti L, Prost-Squarcioni C, Ingen-Housz-Oro S, Caux F, Bernard P, Bedane C, Alexandre M, Dereure O, Quereux G, Le Bidre E, Plée J, Picard-Dahan C, Le Roux-Villet C, Duvert-Lehembre S, Richard MA, Delaporte E, Debarbieux S, Jullien D, D'Incan M, Konstantinou MP, Bouaziz JD, Tancrède-Bohin E, Doutre MS, Bourgault Villada I, Cordel N, Sassolas B, Viguier MA, Mellottée B, Jouen F, Hebert V, Joly P. [Update of the French recommendations for the management of pemphigus]. Ann Dermatol Venereol 2019; 146:279-286. [PMID: 30929874 DOI: 10.1016/j.annder.2019.01.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 11/24/2018] [Accepted: 01/23/2019] [Indexed: 01/29/2023]
Affiliation(s)
- L Jelti
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France.
| | - C Prost-Squarcioni
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - S Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France
| | - F Caux
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - P Bernard
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - C Bedane
- Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France
| | - M Alexandre
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - O Dereure
- Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France
| | - G Quereux
- Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France
| | - E Le Bidre
- Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France
| | - J Plée
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - C Picard-Dahan
- Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France
| | - C Le Roux-Villet
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - S Duvert-Lehembre
- Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France
| | - M-A Richard
- EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France
| | - E Delaporte
- Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France
| | - S Debarbieux
- Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France
| | - D Jullien
- Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France
| | - M D'Incan
- Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France
| | - M-P Konstantinou
- Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France
| | - J-D Bouaziz
- Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - E Tancrède-Bohin
- Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - M-S Doutre
- Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France
| | - I Bourgault Villada
- Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France
| | - N Cordel
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe
| | - B Sassolas
- Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France
| | - M-A Viguier
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - B Mellottée
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - F Jouen
- Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| | - V Hebert
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France
| | - P Joly
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France
| | -
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France; Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France; Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France; Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France; Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France; Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France; Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France; Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France; EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France; Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France; Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France; Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe; Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France; Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| | -
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France; Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France; Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France; Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France; Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France; Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France; Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France; Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France; EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France; Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France; Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France; Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe; Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France; Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| |
Collapse
|
19
|
Abstract
A convenient strategy for synthesis of a pentaerythritol derivative diacetal containing azo functions is presented; NMR data are discussed and are in good agreement with the molecular structure.
Collapse
Affiliation(s)
- G. Lemercier
- Laboratoire de Chimie, UMR CNRS / ENS-Lyon, 46 Allée d'Italie, 69364 Lyon Cédex 07, France
| | - M. Alexandre
- Laboratoire de Chimie, UMR CNRS / ENS-Lyon, 46 Allée d'Italie, 69364 Lyon Cédex 07, France
| | - J.-C. Mulatier
- Laboratoire de Chimie, UMR CNRS / ENS-Lyon, 46 Allée d'Italie, 69364 Lyon Cédex 07, France
| | - C. Andraud
- Laboratoire de Chimie, UMR CNRS / ENS-Lyon, 46 Allée d'Italie, 69364 Lyon Cédex 07, France
| |
Collapse
|
20
|
Seta V, Le Roux-Villet C, Mellottée B, Taïeb C, Alexandre M, Caux F, Joly P, Falissard B, Prost-Squarcioni C. Construction d’un questionnaire Fardeau pour les pemphigus et les pemphigoïdes des muqueuses. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Hebert V, Vermeulin T, Prost-Squarcioni C, Picard-Dahan C, Duvert-Lehembre S, Bruno L, Marie-Aleth R, Bernard P, Dupuy A, Bouaziz JD, Oro S, Dalac-Rat S, Delaporte E, Avenel-Audran M, Sassolas B, Alexandre M, Caux F, D’Incan M, Bedane C, Quereux G, Machet L, Dereure O, Skowron F, Franck N, Beylot-Barry M, Doutre MS, Debarbieux S, Jullien D, Misery L, Musette P, Paul C, Vabres P, Bénéton N, Dupin N, Houivet E, Joly P. Comparaison des coûts de santé du traitement de première ligne par rituximab par rapport à la corticothérapie standard chez les patients pemphigus nouvellement diagnostiqués. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Alahmari AA, Sreekumar B, Patel V, Ashat M, Alexandre M, Uduman AK, Akinbiyi EO, Ceplenski A, Shugrue CA, Kolodecik TR, Tashkandi N, Messenger SW, Groblewski GE, Gorelick FS, Thrower EC. Cigarette toxin 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces experimental pancreatitis through α7 nicotinic acetylcholine receptors (nAChRs) in mice. PLoS One 2018; 13:e0197362. [PMID: 29870540 PMCID: PMC5988302 DOI: 10.1371/journal.pone.0197362] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Accepted: 05/01/2018] [Indexed: 01/29/2023] Open
Abstract
Clinical studies have shown that cigarette smoking is a dose-dependent and independent risk factor for acute pancreatitis. Cigarette smoke contains nicotine which can be converted to the potent receptor ligand and toxin, NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone]. Previously, we have shown that NNK induces premature activation of pancreatic zymogens in rats, an initiating event in pancreatitis, and this activation is prevented by pharmacologic inhibition of nicotinic acetylcholine receptors (nAChR). In this study, we determined whether NNK mediates pancreatitis through the α7 isoform of nAChR using α7nAChR knockout mice. PCR analysis confirmed expression of non-neuronal α7nAChR in C57BL/6 (WT) mouse and human acinar cells. NNK treatment stimulated trypsinogen activation in acini from WT but not α7nAChR-/- mice. NNK also stimulated trypsinogen activation in human acini. To further confirm these findings, WT and α7nAChR-/- mice were treated with NNK in vivo and markers of pancreatitis were measured. As observed in acini NNK treatment induced trypsinogen activation in WT but not α7nAChR-/- mice. NNK also induced other markers of pancreatitis including pancreatic edema, vacuolization and pyknotic nuclei in WT but not α7nAChR-/- animals. NNK treatment led to increased neutrophil infiltration, a marker of inflammation, in WT mice and to a significantly lesser extent in α7nAChR-/- mice. We also examined downstream targets of α7nAChR activation and found that calcium and PKC activation are involved down stream of NNK stimulation of α7nAChR. In this study we used genetic deletion of the α7nAChR to confirm our previous inhibitor studies that demonstrated NNK stimulates pancreatitis by activating this receptor. Lastly, we demonstrate that NNK can also stimulate zymogen activation in human acinar cells and thus may play a role in human disease.
Collapse
Affiliation(s)
- A. A. Alahmari
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - B. Sreekumar
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - V. Patel
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - M. Ashat
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - M. Alexandre
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - A. K. Uduman
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - E. O. Akinbiyi
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - A. Ceplenski
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - C. A. Shugrue
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - T. R. Kolodecik
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - N. Tashkandi
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| | - S. W. Messenger
- Department of Nutritional Sciences, University of Wisconsin, Madison, Wisconsin, United States of America
| | - G. E. Groblewski
- Department of Nutritional Sciences, University of Wisconsin, Madison, Wisconsin, United States of America
| | - F. S. Gorelick
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
- Department of Cell Biology, Yale University School of Medicine, New Haven, CT, United States of America
| | - E. C. Thrower
- Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States of America
- Veterans Affairs Connecticut Healthcare, West Haven, CT, United States of America
| |
Collapse
|
23
|
Gaudin O, Seta V, Alexandre M, Bohelay G, Oro S, Bernardeschi C, Schneider P, Mellottee B, Caux F, Prost-Squarcioni C. Pemphigoïdes des muqueuses (PM) et gliptines : étude de 24 cas. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
24
|
Plaquevent M, Tetart F, Fardet L, Oro S, Bernard P, Roussel A, Avenel-Audran M, Chaby G, D’incan M, Souteyrand P, Duvert-Lehembre S, Picard-Dahan C, Jeudy G, Labeille B, Morice C, Richard MA, Bourgault Villada I, Litrowski N, Bara C, Mahe E, Prost C, Alexandre M, Quereux G, Soria A, Thomas-Beaulieu D, Pauwels C, Joly P. Pemphigoïdes bulleuses associées aux gliptines : mythe ou réalité ? Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Le Roux-Villet C, Alexandre M, Mellottee B, Pascal F, Weber P, Soued I, Aucouturier F, Caux F, Prost C. Utilisation du rituximab pour le traitment du pemphigus : étude rétrospective monocentrique de 43 patients. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Ariane M, Estève E, Fougerousse AC, Avenel-Audran M, Quiles-Tsimaratos N, Mery-Brossard L, Pauwels C, Le Guyadec T, Bastien M, Liégeon AL, Pallure V, Girard C, Alexandre M, Khatibi B, Poiraud C, Maccari F, Amy de la Breteque M, Sigal ML, Beauchet A, Mahé E. Utilisation de régimes d’éviction et médecines alternatives chez les patients atteints de psoriasis : une enquête nationale. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Zehou O, Raynaud JJ, Le Roux-Villet C, Alexandre M, Airinei G, Pascal F, Heller M, Lièvre N, Laroche L, Caux F, Benamouzig R, Prost-Squarcioni C. Oesophageal involvement in 26 consecutive patients with mucous membrane pemphigoid. Br J Dermatol 2017; 177:1074-1085. [PMID: 28417469 DOI: 10.1111/bjd.15592] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2017] [Indexed: 01/07/2023]
Abstract
BACKGROUND Oesophageal involvement of mucous membrane pemphigoid (MMP) has not yet been thoroughly described. OBJECTIVES To characterize systematically the endoscopic lesions of a series of patients with oesophageal symptoms seen at a referral centre for autoimmune bullous diseases. METHODS Clinical, endoscopic and immunological findings of consecutively referred patients with MMP with oesophageal involvement, systemic and endoscopic treatments, and follow-up are described. RESULTS Of 477 consecutive patients with MMP consulting between 2002 and 2012, 26 (5·4%) had symptomatic oesophageal involvement. Dysphagia, observed in 23 (88%) patients, was the most frequent symptom. Oesophageal symptoms could be the first sign of MMP. Patients with oesophageal involvement had a mean of three other involved sites. At initial oesophageal endoscopy, 17 of 26 patients had active lesions (intact bullae, erosions and/or erythema), 15 had stricture(s) and 12 had other cicatricial lesions. Systemic therapy alone achieved oesophageal symptom relief for five patients. Dilatation was combined with systemic therapy for 12 patients and was successful in nine; one perforation occurred. CONCLUSIONS Symptomatic oesophageal involvement affected 5·4% of patients with MMP. Dermatologists and gastroenterologists should be aware of these mucocutaneous diseases and their oesophageal involvement, as it could lead to earlier diagnosis and better care. Oesophageal dilatation could be a therapeutic option for symptomatic stricture not relieved by optimized systemic therapy alone.
Collapse
Affiliation(s)
- O Zehou
- Department of Dermatology and Referral Center for Auto-Immune Bullous Diseases, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France
| | - J-J Raynaud
- Department of Gastroenterology, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France
| | - C Le Roux-Villet
- Department of Dermatology and Referral Center for Auto-Immune Bullous Diseases, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France
| | - M Alexandre
- Department of Dermatology and Referral Center for Auto-Immune Bullous Diseases, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France
| | - G Airinei
- Department of Gastroenterology, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France
| | - F Pascal
- Department of Dermatology and Referral Center for Auto-Immune Bullous Diseases, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France
| | - M Heller
- Department of Histology and Referral Center for Auto-Immune Bullous Diseases, UFR Léonard de Vinci, University Paris 13, 93017, Bobigny, France
| | - N Lièvre
- Department of Histology and Referral Center for Auto-Immune Bullous Diseases, UFR Léonard de Vinci, University Paris 13, 93017, Bobigny, France
| | - L Laroche
- Department of Dermatology and Referral Center for Auto-Immune Bullous Diseases, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France
| | - F Caux
- Department of Dermatology and Referral Center for Auto-Immune Bullous Diseases, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France
| | - R Benamouzig
- Department of Gastroenterology, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France
| | - C Prost-Squarcioni
- Department of Dermatology and Referral Center for Auto-Immune Bullous Diseases, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France.,Department of Histology and Referral Center for Auto-Immune Bullous Diseases, UFR Léonard de Vinci, University Paris 13, 93017, Bobigny, France.,Department of Pathology, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France
| |
Collapse
|
28
|
|
29
|
Gottlieb J, Ingen-Housz-Oro S, Alexandre M, Grootenboer-Mignot S, Aucouturier F, Sbidian E, Tancrede E, Schneider P, Regnier E, Picard-Dahan C, Begon E, Pauwels C, Cury K, Hüe S, Bernardeschi C, Ortonne N, Caux F, Wolkenstein P, Chosidow O, Prost-Squarcioni C. Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults. Br J Dermatol 2017; 177:212-222. [PMID: 27995619 DOI: 10.1111/bjd.15244] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/12/2016] [Indexed: 11/27/2022]
Abstract
BACKGROUND Linear IgA bullous dermatosis (LABD) is a clinically and immunologically heterogeneous, subepidermal, autoimmune bullous disease (AIBD), for which the long-term evolution is poorly described. OBJECTIVES To investigate the clinical and immunological characteristics, follow-up and prognostic factors of adult idiopathic LABD. METHODS This retrospective study, conducted in our AIBD referral centre, included adults, diagnosed between 1995 and 2012, with idiopathic LABD, defined as pure or predominant IgA deposits by direct immunofluorescence. Clinical, histological and immunological findings were collected from charts. Standard histology was systematically reviewed, and indirect immunofluorescence (IIF) on salt-split skin (SSS) and immunoblots (IBs) on amniotic membrane extracts using anti-IgA secondary antibodies were performed, when biopsies and sera obtained at diagnosis were available. Prognostic factors for complete remission (CR) were identified using univariate and multivariate analyses. RESULTS Of the 72 patients included (median age 54 years), 60% had mucous membrane (MM) involvement. IgA IIF on SSS was positive for 21 of 35 patients tested; 15 had epidermal and dermal labellings. Immunoelectron microscopy performed on the biopsies of 31 patients labelled lamina lucida (LL) (26%), lamina densa (23%), anchoring-fibril zone (AFz) (19%) and LL+AFz (23%). Of the 34 IgA IBs, 22 were positive, mostly for LAD-1/LABD97 (44%) and full-length BP180 (33%). The median follow-up was 39 months. Overall, 24 patients (36%) achieved sustained CR, 19 (29%) relapsed and 35% had chronic disease. CR was significantly associated with age > 70 years or no MM involvement. No prognostic immunological factor was identified. CONCLUSIONS Patients with LABD who are < 70 years old and have MM involvement are at risk for chronic evolution.
Collapse
Affiliation(s)
- J Gottlieb
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France
| | - S Ingen-Housz-Oro
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France
| | - M Alexandre
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Avicenne Hospital, Bobigny, France
| | - S Grootenboer-Mignot
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Department of Autoimmunity and Hypersensitivity, APHP, Bichat Hospital, Paris, France
| | - F Aucouturier
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Immunology Department, APHP, Saint-Louis Hospital, Paris, France
| | - E Sbidian
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Inserm, Centre d'Investigation Clinique 1430, Créteil, France
| | - E Tancrede
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Saint-Louis Hospital, Paris, France
| | - P Schneider
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Saint-Louis Hospital, Paris, France.,Pathology Department, APHP, Saint-Louis Hospital, Paris, France
| | - E Regnier
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Tarnier Hospital, Paris, France
| | - C Picard-Dahan
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Bichat Hospital, Paris, France
| | - E Begon
- Dermatology Department, René-Dubos Hospital, Pontoise, France
| | - C Pauwels
- Dermatology Department, Saint-Germain Hospital, Saint-Germain, France
| | - K Cury
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Tenon Hospital, Paris, France
| | - S Hüe
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Immunology Department, APHP, Henri-Mondor Hospital, Créteil, France
| | - C Bernardeschi
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Pathology Department, APHP, Saint-Louis Hospital, Paris, France
| | - N Ortonne
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Pathology Department, APHP, Henri-Mondor Hospital, Créteil, France
| | - F Caux
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.,Université Paris 13, Bobigny, France
| | - P Wolkenstein
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France
| | - O Chosidow
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Inserm, Centre d'Investigation Clinique 1430, Créteil, France
| | - C Prost-Squarcioni
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.,Université Paris 13, Bobigny, France.,Pathology Department, APHP, Avicenne Hospital, Bobigny, France
| |
Collapse
|
30
|
Viala M, Alexandre M, Thézenas S, Lamy PJ, Bibeau F, Gutowski M, Colombo PE, Romieu G, Jacot W, Guiu S. Abstract P6-09-28: Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Intermediate-risk early breast cancer (EBC) is a heterogeneous group in which adjuvant chemotherapy decision prove to be difficult. Clinical and pathological criteria might be insufficient to determine the best therapeutic options for patients, and validated biomarkers are urgently needed to help decision making, such as the LOE-I uPA/PAI-1 biomarker. The aim of this study is to evaluate the clinical outcome of a large, unselected, ER+/HER2- pN0 EBC cohort of patients in whom the routine clinical decision process included a prospective uPA/PAI-1 determination.
Methods: This monocentric retrospective study included 520 ER+/HER2- pN0/M0 EBC patients who had curative surgery in our center between 2006 and 2011. Adjuvant therapeutic strategy was decided based on clinico-pathological data, altogether with a routine prospective determination of uPA/PAI-1 tumor levels. We evaluated the correlation between uPA/PAI-1 levels, classical clinico-pathological variables and the patient's outcome (relapse free survival, RFS; overall survival, OS).
Results: Median age was 54 years (range 27-85). 75% of tumors were classified T1, 25% T2 and above. We found 80.8% of ductal carcinomas, 12.3% of lobular carcinomas and 6.9% of other histological types. SBR grade 1-2 represented 82.5% of our cohort versus 17.5% of grade 3. Mitotic count was <10 in 63.5% of cases, and ≥10 in 36.5%. Peri-tumoral invasion (PVI) was seen in 17% of tumors. Progesterone receptors (PR) were positive in 79.6% of cases. Median follow-up was 5.4 years. 5 and 10 years RFS were respectively 95% and 89% (n=33 local or metastatic relapse). 5 year OS was 96.3%. We found 40% of low uPA/PAI-1 levels, and 60% of high uPA and/or PAI-1 levels. By using uPA/PAI-1 levels in our adjuvant treatment decision-making, 75% of patients with low uPA/PAI-1 levels did not received chemotherapy and 60% of patients with high uPA and/or PAI-1 levels received chemotherapy. 98.3% of our patients received endocrine therapy as adjuvant treatment for at least 5 years. No statistical significant correlation was found between uPA/PAI-1 levels and RFS (p=0.3) or OS (p=0.28). In univariate analysis, tumor size (p=0.048; p=0.0694), histological grade (p=0.007; p=0.0142), PR status (p=0.001; p=0.0002) and mitotic count (p=0.0001; p=0.0001) were statistically correlated with RFS and OS, respectively. Using cox regression model, PR status (p<0.003) and mitotic count (p<0.001) appeared to be strongly correlated with RFS. No changes in significant variables were seen when the analyses were restricted to the grade 2 subgroup (n=339).
Conclusion: The individualization of patients' treatment using uPA/PAI-1 tumor levels allows the reversion of the well-known poor prognostic impact of high uPA/PAI-1 levels and strongly support the use of this LOE-I biomarker in clinical practice. PR status and mitotic activity remains independent major prognostic factors in optimally treated patients. The evaluation of the additional impact of multigene signature in this setting needs to be performed. Longer 10-years follow-up needs to be done in this ER+/HER2- subgroup, particularly to evaluate the risk of late relapse after endocrine therapy.
Citation Format: Viala M, Alexandre M, Thézenas S, Lamy P-J, Bibeau F, Gutowski M, Colombo P-E, Romieu G, Jacot W, Guiu S. Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-28.
Collapse
Affiliation(s)
- M Viala
- Institut Cancerologie Montpellier, Montpellier, France; INSERM U1194 - IRCM, Montpellier, France; LABOSUD Ocbiologie, Montpellier, France
| | - M Alexandre
- Institut Cancerologie Montpellier, Montpellier, France; INSERM U1194 - IRCM, Montpellier, France; LABOSUD Ocbiologie, Montpellier, France
| | - S Thézenas
- Institut Cancerologie Montpellier, Montpellier, France; INSERM U1194 - IRCM, Montpellier, France; LABOSUD Ocbiologie, Montpellier, France
| | - P-J Lamy
- Institut Cancerologie Montpellier, Montpellier, France; INSERM U1194 - IRCM, Montpellier, France; LABOSUD Ocbiologie, Montpellier, France
| | - F Bibeau
- Institut Cancerologie Montpellier, Montpellier, France; INSERM U1194 - IRCM, Montpellier, France; LABOSUD Ocbiologie, Montpellier, France
| | - M Gutowski
- Institut Cancerologie Montpellier, Montpellier, France; INSERM U1194 - IRCM, Montpellier, France; LABOSUD Ocbiologie, Montpellier, France
| | - P-E Colombo
- Institut Cancerologie Montpellier, Montpellier, France; INSERM U1194 - IRCM, Montpellier, France; LABOSUD Ocbiologie, Montpellier, France
| | - G Romieu
- Institut Cancerologie Montpellier, Montpellier, France; INSERM U1194 - IRCM, Montpellier, France; LABOSUD Ocbiologie, Montpellier, France
| | - W Jacot
- Institut Cancerologie Montpellier, Montpellier, France; INSERM U1194 - IRCM, Montpellier, France; LABOSUD Ocbiologie, Montpellier, France
| | - S Guiu
- Institut Cancerologie Montpellier, Montpellier, France; INSERM U1194 - IRCM, Montpellier, France; LABOSUD Ocbiologie, Montpellier, France
| |
Collapse
|
31
|
Toulouse J, Leneveu MC, Brouard J, Alexandre M. Comparaison des représentations des soins palliatifs des internes de pédiatrie à celles des internes d’onco-hématologie – étude qualitative. Arch Pediatr 2016; 23:577-83. [DOI: 10.1016/j.arcped.2016.03.053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2015] [Revised: 03/05/2016] [Accepted: 03/07/2016] [Indexed: 10/21/2022]
|
32
|
Seta V, Alexandre M, Zumelzu C, Oro S, Bernardeschi C, Schneider P, Le Roux-Villet C, Pascal F, Weber P, Doan S, Soued I, Raynaud J, Benamouzig R, Vibert J, Tancrède E, Dupin N, Laroche L, Caux F, Tubach F, Prost-Squarcioni C, Gault N. Morbidité et facteurs pronostiques dans la pemphigoïde cicatricielle : étude de cohorte rétrospective. Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.03.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
33
|
Boulard C, Duvert Lehembre S, Picard‐Dahan C, Kern J, Zambruno G, Feliciani C, Marinovic B, Vabres P, Borradori L, Prost‐Squarcioni C, Labeille B, Richard M, Ingen‐Housz‐Oro S, Houivet E, Werth V, Murrell D, Hertl M, Benichou J, Joly P, Hofmann S, Camaioni B, Didona B, Fania L, Della Torre R, Caux F, Alexandre M, Paul C, Bulai Livideanu C, Delaporte E, Dupuy A, Avenel‐Audran M, Schmidt E, Schumacher N, Bagot M, Tancrede‐Bohin E, Bouaziz J, D'Incan M, Quereux G, Skowron F, Beylot‐Barry M, Doutre M, Bedane C, Bernard P, Machet L, Jullien ., Debarbieux S, Dereure O, Hünefeld C, Schanz S, Franck N, Maillard H, Misery L, Sassolas B, Abasq C, Bouyeure A, Lagoutte P, Ferranti V. Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score (
ABSIS
) and Pemphigus Disease Area Index (
PDAI
) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol 2016; 175:142-9. [DOI: 10.1111/bjd.14405] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/14/2016] [Indexed: 11/27/2022]
Affiliation(s)
- C. Boulard
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | - S. Duvert Lehembre
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | - C. Picard‐Dahan
- Department of Dermatology Bichat University Hospital AP‐HP Paris France
| | - J.S. Kern
- Department of Dermatology Medical Center University of Freiburg Freiburg Germany
| | - G. Zambruno
- Laboratory of Molecular and Cell Biology Istituto Dermopatico dell'Immacolata IRCCS Via Monti di Creta 104 00167 Roma Italy
| | - C. Feliciani
- Policlinico Gemelli – Università Cattolica del ‘Sacro Cuore’ Largo Gemelli 8 00168 Roma Italy
| | - B. Marinovic
- University Hospital Center Zagreb Department of Dermatology and Venereology Salata 4 10000 Zagreb Croatia
| | - P. Vabres
- Department of Dermatology Dijon University Hospital Dijon France
| | - L. Borradori
- Department of Dermatology Universitätsklinik für Dermatologie Inselspital CH‐3010 Bern Switzerland
| | - C. Prost‐Squarcioni
- Department of Dermatology Avicenne Hospital University Paris 13 Bobigny France
| | - B. Labeille
- Department of Dermatology Saint Etienne University Hospital Saint Etienne France
| | - M.A. Richard
- Aix‐Marseille University UMR 911 INSERM CRO2 ‘Centre de Recherche en Oncologie Biologique et Oncophamacologie’ Department of Dermatology Hôpital Timone Assistance Publique des Hôpitaux de Marseille 264 Rue Saint Pierre 13385 Marseille France
| | - S. Ingen‐Housz‐Oro
- Department of Dermatology Henri Mondor University Hospital AP‐HP Créteil France
| | - E. Houivet
- Department of Biostatistics INSERM U657 Rouen University Hospital University of Rouen Rouen France
| | - V.P. Werth
- Department of Dermatology University of Pennsylvania, and Philadelphia VAMC Philadelphia PA U.S.A
| | - D.F. Murrell
- Department of Dermatology St George Hospital University of NSW Sydney Australia
| | - M. Hertl
- Department of Dermatology Philipps University Marburg Marburg Germany
| | - J. Benichou
- Department of Biostatistics INSERM U657 Rouen University Hospital University of Rouen Rouen France
| | - P. Joly
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Seta V, Gault N, Alexandre M, Zumelzu C, Oro S, Bernardeschi C, Schneider P, Le Roux Villet C, Pascal F, Weber P, Doan S, Soued I, Raynaud JJ, Lièvre N, Heller M, Tancrède E, Benamouzig R, Vibert JF, Dupin N, Wolkenstein P, Laroche L, Caux F, Tubach F, Prost-Squarcioni C. Morbidité et facteurs pronostiques dans la pemphigoïde cicatricielle : étude rétrospective sur 121 patients. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Hebert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Reproductibilité inter-observateur des scores de sévérité du pemphigus ABSIS et PDAI. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
36
|
Rousset L, Bohelay G, Caux F, Levy A, Le Roux Villet C, Brauner M, Tandjaoui H, Gille T, Laroche L, Prost C, Alexandre M. Pemphigoïde des muqueuses avec atteinte bronchique spécifique développée sur métaplasie malpighienne : 2 cas. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
37
|
Houivet E, Hebert V, Boulard C, Vaillant M, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Corrélation entre les scores de sévérité clinique (ABSIS, PDAI, PGA), la qualité de vie (DLQI) et les taux d’Ac anti-desmogléine 1 et 3 dans le suivi du pemphigus. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
38
|
Joly P, Houivet E, Prost C, Maho-Vaillant M, Picard Dahan C, Duvert Lehembre S, Labeille B, Richard M, Bernard P, Dupuy A, Bouaziz J, Oro S, Chosidow O, Vabres P, Delaporte E, Avenel M, Alexandre M, Caux F, Incan M, Bedane C, Quereux G, Machet L, Dereure O, Skowron F, Franck N, Beylot-Barry M, Doutre M, Beneton N, Debarbieux S, Jullien D, Misery L, Ferranti V, Benichou J, Musette P. Étude randomisée évaluant l’efficacité et la tolérance du rituximab associé à une corticothérapie allégée par rapport à une corticothérapie standard dans le traitement du pemphigus. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
39
|
Alexandre M, Seta V, Zumelzu C, Vibert JF, Le Roux Villet C, Doan S, Soued I, Pascal F, Lièvre N, Heller M, Caux F, Laroche L, Prost C. Efficacité du rituximab dans les pemphigoïdes des muqueuses. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Alexandre M, Votino C, De Noose L, Cos Sanchez T, Gaugue J, Jani J. The impact of prior medical termination of pregnancy on the mother’s early relationship with a subsequent infant. J Matern Fetal Neonatal Med 2015; 29:1238-43. [DOI: 10.3109/14767058.2015.1043260] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
41
|
Poirier E, Soued I, Alexandre M, Boussoura S, Lamberto C, Uzunhan Y, Gharbi N, Pascal F, Doan S, Brillet PY, Caux F, Laroche L, Prost-Squarcioni C. Pemphigoïde des muqueuses avec sténoses laryngées ou trachéales : série de 11 cas. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
42
|
Zumelzu C, Alexandre M, Do-Pham TG, De Prost N, Caux F, Prost C, Laroche L. Surinfection à HSV1 d’érosions chroniques au cours d’une épidermolyse bulleuse acquise (EBA). Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
43
|
Gottlieb J, Oro S, Alexandre M, Sbidian E, Aucouturier F, Tancrede E, Schneider P, Regnier E, Picard-Dahan C, Begon E, Pauwels C, Cury K, Bernadeschi C, Ortonne N, Grootenboer-Mignot S, Caux F, Chosidow O, Wolkenstein P, Prost-Squarcioni C. Les dermatoses à IgA linéaires (DIgAL) idiopathiques de l’adulte : 72 cas. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
44
|
Silva Júnior LM, Alexandre M, Gonçalves L, Silva FS, Caetano AG. Variations in The Vascular Supply of Pancreas and Transverse Colon: A Case Report. INT J MORPHOL 2014. [DOI: 10.4067/s0717-95022014000100032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
45
|
Commin M, Prost C, Picard-Dahan C, Duvert-Lehembre S, Labeille B, Paul C, Richard M, Dalac S, Bernard P, Dupuy A, Bouaziz J, Oro SIH, Avenel M, Sassolas B, Alexandre M, Caux F, D’Incan M, Delaporte E, Bedane C, Quereux G, Machet L, Vabres P, Dereure O, Skowron F, Franck N, Barry MB, Maillard H, Debardieux S, Jullien D, Misery L, Ferranti V, Joly P. Analyse intermédiaire de l’efficacité du rituximab comme traitement de première intention du pemphigus. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
46
|
Zehou O, Alexandre M, Raynaud JJ, Benamouzig R, Laroche L, Prost C. Pemphigoïde des muqueuses (PM) avec atteinte œsophagienne : série de 26 cas. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
47
|
Boulard C, Bouyeure A, Houivet E, Borradori L, Huenefeld C, Schmidt E, Marinovic B, Zambruno G, Feliciani C, Prost C, Picard-Dahan C, Duvert Lehembre S, Labeille B, Paul C, Richard M, Dalac S, Bernard P, Dupuy A, Caux F, Bouaziz J, Oro S, Avenel-Audran M, Misery L, Sassolas B, Alexandre M, D’Incan M, Delaporte E, Bedane C, Quereux G, Machet L, Vabre P, Dereure O, Skowron F, Franck N, Beylot-Barry M, Beneton Benhard N, Debarbieux S, Jullien D, Benichou J, Ferranti V, Murrell D, Hertl M, Joly P. Qualité de vie chez les patients atteints de pemphigus : corrélation avec le type et la sévérité du pemphigus. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
48
|
Seta V, Aucouturier F, Bonnefoy J, Le Roux C, Mignot S, Pendaries V, Alexandre M, Heller M, Caux F, Lièvre N, Titeux M, Hovnanian A, Prost-Squarcioni C. L’Elisa-collagène 7 (C7) sur la protéine entière (Elisa-C7 total) est plus sensible que celui sur les domaines NC1 et NC2 (Elisa-C7-NC1/NC2) pour le diagnostic d’épidermolyse bulleuse acquise (EBA). Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Alexandre M, Le Roux C, Doan S, Soued I, Pascal F, Heller M, Lièvre N, Caux F, Laroche L, Prost C. Morbidité à un an de la pemphigoïde cicatricielle : étude rétrospective sur 60 cas. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
50
|
Munyangango E, Le Roux-Villet C, Doan S, Pascal F, Soued I, Alexandre M, Heller M, Lièvre N, Aucouturier F, Caux F, Laroche L, Prost-Squarcioni C. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid. Br J Dermatol 2013; 168:381-90. [DOI: 10.1111/bjd.12041] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|